We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug
conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and …

Despite the emergence of advanced therapeutics such as targeted therapy and
immunotherapy in the modern oncology, cytotoxic chemotherapy still remains as the first-line …

Monomethyl auristatin E (MMAE) is one of the most commonly used payloads for developing
antibody–drug conjugates (ADC). However, limited studies have comprehensively …

Many anticancer drugs exhibit high systemic off-target toxicities causing severe side effects.
Peptide–drug conjugates (PDCs) that target tumor-specific receptors such as integrin αvβ6 …

Prostate cancer is the second most common type of cancer among men. Its main method of
treatment is chemotherapy, which has a wide range of side effects. One of the solutions to …

The ADC XMT-1522 consists of a novel human IgG1 anti-HER2 monoclonal antibody and a
novel, auristatin-based cytotoxic payload (Auristatin F-hydroxypropylamide, AF-HPA). An …

Antibody–drug conjugates (ADCs) have demonstrated clinical benefits that have led to the
recent FDA approval of KADCYLA and ADCETRIS. Most ADCs that are currently in clinical …

A simple liquid chromatography–quadrupole-time-of-flight–mass spectrometric assay (LC-
TOF-MS/MS) has been developed for the evaluation of metabolism and pharmacokinetic …

The auristatin class of microtubule destabilizers are highly potent cytotoxic agents against
several cancer cell types when delivered as antibody drug conjugates. Here we describe the …

Antibody-drug conjugates (ADCs) are targeted therapies, mainly used in oncology,
consisting in a three-component molecular architecture combining a highly potent drug …